Pulmonary fibrosis Flashcards

1
Q

Clinical signs of pulmonary fibrosis

A
  • Clubbing, central cyanosis and tachypnoea
  • Fine end‐inspiratory crackles (like Velcro® which do not change with coughing)
  • Signs of associated autoimmune diseases, e.g. RA (hands), SLE and systemic sclerosis (face and hands)
  • Signs of treatment, e.g. Cushingoid from steroids
  • Discoloured skin (grey) – amiodarone
  • Unless there are any associated features then describe your findings as pulmonary fibrosis, which is a clinical description pending further differentiation following investigations
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Investigation for pulmonary fibrosis

A
  • Bloods: ESR, rheumatoid factor and ANA
  • CXR: reticulonodular changes; loss of definition of either heart border; small lungs
  • ABG: type I respiratory failure
  • Lung function tests:
    ⚬⚬ FEV1/FVC > 0.8 (restrictive)
    ⚬⚬ Low TLC (small lungs)
    ⚬⚬ Reduced TLco and KCO
  • Bronchoalveolar lavage: main indication is to exclude any infection prior to immunosuppressants plus if lymphocytes > neutrophils indicate a better response to steroids and a better prognosis (sarcoidosis)
  • High-resolution CT scan: distribution helps with diagnosis; bibasal subpleural honeycombing typical of UIP; widespread ground glass shadowing more likely to be non‐specific interstitial pneumonia often associated with autoimmune disease; if apical in distribution then think of sarcoidosis, ABPA, old TB, hypersensitivity pneumonitis, Langerhan’s cell histiocytosis.
  • Lung biopsy (associated morbidity ~7%)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Treatment of pulmonary fibrosis

A
  • Pulmonary rehabilitation
  • Immunosuppression if likely to be inflammatory; i.e. non‐specific interstitial pneumonia e.g. steroids: combination of steroids and azathioprine no longer used following results of PANTHER trial which showed increased morbidity on this combination
  • Pirfenidone, Nintedanib (an antifibrotic agent) ‐ for UIP when FEV1 50–80% predicted (NICE recommended)
  • N‐acetyl cycsteine – free radical scavenger
  • Single lung transplant
  • NB: Beware single lung transplantation patient – unilateral fine crackles and contralateral thoracotomy scar with normal breath sounds
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Prognosis of pulmonary fibrosis

A
  • Very variable: depends on aetiology
  • Highly cellular with ground glass infiltrate – responds to immunosuppression: 80% 5‐year survival
  • Honeycombing on CT – no response to immunosuppression: 80% 5‐year mortality
  • There is an increased risk of bronchogenic carcinoma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Causes of basal fibrosis

A
  • Usual interstitial pneumonia (UIP)
  • Asbestosis
  • Connective tissue diseases
  • Aspiration
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Causes of fibrotic shadowing on CXR

A

Upper Zone (TRASHE)
- TB
- Radiotherapy
- Ankylosing spondylitis
- Sarcoidosis
- Histoplasmosis, Histiocytosis X
- Extrinsic allergic alveolitis
Mid Zone
- Progressive massive Fibrosis
Lower zone
- Usual interstitial pneumonia (UIP)
- Asbestosis
- Connective tissue disease
- Aspiration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly